<?xml version="1.0" encoding="UTF-8"?>
<!-- Dublin Core rendering of ae4ae4f8-9322-4c48-9833-7a08aca631ef, generated by folio-assistant-core/scripts/dc-render.ts. Do not edit. -->
<metadata xmlns="https://litlfred.github.io/folio-assistant-core/v0/ns/dspace/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <dcterms:creator xml:lang="en">World Health Organization</dcterms:creator>
  <dcterms:spatial>Geneva</dcterms:spatial>
  <dc:date>2012-06-16T15:02:23Z</dc:date> <!-- dc.date.accessioned -->
  <dcterms:available xsi:type="dcterms:W3CDTF">2012-06-16T15:02:23Z</dcterms:available>
  <dcterms:created xsi:type="dcterms:W3CDTF" xml:lang="en">2011</dcterms:created>
  <dcterms:issued xsi:type="dcterms:W3CDTF" xml:lang="en">2011-12-31</dcterms:issued>
  <dcterms:description xml:lang="en">70 p.</dcterms:description>
  <dcterms:abstract>This policy statement provides evidence-based recommendations on the use of commercial interferon-gamma release assays (IGRAs) for tuberculosis (TB) in low- and middle-income countries, particularly settings with a high TB and/or HIV burden. Based on systematic reviews and GRADE assessment, it evaluates IGRAs for diagnosis of active TB, detection of latent TB infection (LTBI) in children and people living with HIV, screening of health care workers and contacts, outbreak investigations, and prediction of progression to active disease.

The evidence was generally of low or very low quality and did not demonstrate superior performance of IGRAs over the tuberculin skin test (TST). WHO recommends that IGRAs and the TST not be used to diagnose active TB or identify individuals at risk of developing active disease, and that IGRAs not replace the TST for LTBI diagnosis in children, people living with HIV, or contacts. Given comparable performance, greater cost and technical complexity, replacing the TST with IGRAs as a public health intervention in resource-constrained settings is not recommended.</dcterms:abstract>
  <dc:identifier>9789241502672</dc:identifier> <!-- dc.identifier.isbn -->
  <dcterms:identifier xsi:type="dcterms:URI">https://iris.who.int/handle/10665/44759</dcterms:identifier>
  <dcterms:language>English</dcterms:language>
  <dcterms:language xsi:type="dcterms:RFC4646" xml:lang="en">en</dcterms:language>
  <dcterms:publisher>World Health Organization</dcterms:publisher>
  <dcterms:subject>WHO guideline</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="en">Interferon-gamma</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="en">Tuberculosis, Pulmonary</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="en">Immunoassay</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="en">Reagent Kits, Diagnostic</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="en">Developing Countries</dcterms:subject>
  <dcterms:subject xsi:type="dcterms:MESH" xml:lang="en">Guideline</dcterms:subject>
  <dc:subject xml:lang="en">diagnosis</dc:subject> <!-- dc.subject.meshqualifier -->
  <dc:subject xml:lang="en">methods</dc:subject> <!-- dc.subject.meshqualifier -->
  <dcterms:subject xml:lang="en">Chronic Diseases and their Control</dcterms:subject>
  <dcterms:title xml:lang="en">Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries : policy statement</dcterms:title>
</metadata>
